Rocket Pharmaceuticals, Inc. (RCKT)
NASDAQ: RCKT · Real-Time Price · USD
3.320
-0.100 (-2.92%)
At close: Dec 5, 2025, 4:00 PM EST
3.350
+0.030 (0.90%)
After-hours: Dec 5, 2025, 7:48 PM EST
Rocket Pharmaceuticals Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
| TTM
| FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
| Sep '25 Sep 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 |
| Selling, General & Admin | 97.15 | 101.96 | 70.32 | 58.77 | 41.77 | 28.87 | |
| Research & Development | 150.03 | 171.24 | 186.34 | 165.07 | 124.48 | 105.44 | |
| Operating Expenses | 247.18 | 273.21 | 256.66 | 223.84 | 166.25 | 134.3 | |
| Operating Income | -247.18 | -273.21 | -256.66 | -223.84 | -166.25 | -134.3 | |
| Interest Expense | -1.89 | -1.89 | -1.88 | -1.86 | -2.98 | -6.97 | |
| Interest & Investment Income | 4.14 | 8.27 | 5.29 | 3.89 | 3.07 | 2.15 | |
| EBT Excluding Unusual Items | -244.93 | -266.82 | -253.25 | -221.82 | -166.16 | -139.12 | |
| Merger & Restructuring Charges | -3.3 | - | -3 | - | - | - | |
| Gain (Loss) on Sale of Investments | 7.31 | 8.08 | 10.65 | -0.05 | -2.91 | -0.58 | |
| Pretax Income | -240.91 | -258.75 | -245.6 | -221.86 | -169.07 | -139.7 | |
| Net Income | -240.91 | -258.75 | -245.6 | -221.86 | -169.07 | -139.7 | |
| Net Income to Common | -240.91 | -258.75 | -245.6 | -221.86 | -169.07 | -139.7 | |
| Shares Outstanding (Basic) | 108 | 95 | 84 | 68 | 63 | 55 | |
| Shares Outstanding (Diluted) | 108 | 95 | 84 | 68 | 63 | 55 | |
| Shares Change (YoY) | 14.70% | 12.85% | 23.27% | 7.77% | 14.18% | 13.00% | |
| EPS (Basic) | -2.24 | -2.73 | -2.92 | -3.26 | -2.67 | -2.52 | |
| EPS (Diluted) | -2.24 | -2.73 | -2.92 | -3.26 | -2.67 | -2.52 | |
| Free Cash Flow | -202.79 | -215.59 | -211.35 | -186.5 | -128.78 | -95.25 | |
| Free Cash Flow Per Share | -1.89 | -2.27 | -2.52 | -2.74 | -2.04 | -1.72 | |
| EBITDA | -236.01 | -263.83 | -249.56 | -217.58 | -160.88 | -133.16 | |
| D&A For EBITDA | 11.17 | 9.38 | 7.1 | 6.27 | 5.37 | 1.15 | |
| EBIT | -247.18 | -273.21 | -256.66 | -223.84 | -166.25 | -134.3 | |
Source: S&P Capital IQ. Standard template.
Financial Sources.